Primary objective The objective of this study is to compare anti-Xa levels obtained with a standard high dose thrombosis prophylaxis in COVID-19 intensive care-patients compared with anti-Xa levels obtained with a normal dose thrombosis prophylaxis in non-COVID-19 intensive care patients. Secondary objectives 1. To determine the incidence of anti Xa levels out of range of the established target anti Xa level in both groups. 2. To determine the influence of relevant co-variates on the anti-Xa level in the COVID-19 and non-COVID-19 group.
Study Type
OBSERVATIONAL
Enrollment
62
Blood sampling for the determination of anti-Xa peak levels 4 hours after administration of nadroparin sc.
Monique de Maat
Arnhem, Netherlands
Evaluation of anti-Xa peak level
U/ml
Time frame: 2 years
Percentage of anti-Xa levels within target range
Amount of levels within target range (in %)
Time frame: 2 years
Influence of covariates (nadroparin dosage, gender, age, weight, BMI, COVID-19, APACHE IV, vasopressor use, eGFR, fluid balance, CRP) on anti-Xa level
relevant correlation
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.